Lipoid pneumonia secondary prevention: Difference between revisions

	Lipoid pneumonia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Lipoid pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lipoid pneumonia secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lipoid pneumonia secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lipoid pneumonia secondary prevention
CDC on Lipoid pneumonia secondary prevention
Lipoid pneumonia secondary prevention in the news
Blogs on Lipoid pneumonia secondary prevention
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Lipoid pneumonia secondary prevention

Latest revision as of 02:52, 23 October 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD [2]

There are no established measures for the secondary prevention of lipoid pneumonia.

There are no established measures for the secondary prevention oflipoid pneumonia.^[1]

↑ Marchiori, Edson; Zanetti, Gláucia; Mano, Claudia Mauro; Hochhegger, Bruno (2011). "Exogenous lipoid pneumonia. Clinical and radiological manifestations". Respiratory Medicine. 105 (5): 659–666. doi:10.1016/j.rmed.2010.12.001. ISSN 0954-6111.

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{lipoid pnumonia}}
+{{lipoid pneumonia}}
+{{CMG}}; {{AE}} {{RG}}
-{{CMG}}; {{AE}}
 ==Overview==
-There are no established measures for the secondary prevention of [disease name].
+There are no established measures for the secondary prevention of lipoid pneumonia.
-OR
-Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
 ==Secondary Prevention==
-There are no established measures for the secondary prevention of [disease name].
+There are no established measures for the secondary prevention oflipoid pneumonia.<ref name="MarchioriZanetti2011">{{cite journal|last1=Marchiori|first1=Edson|last2=Zanetti|first2=Gláucia|last3=Mano|first3=Claudia Mauro|last4=Hochhegger|first4=Bruno|title=Exogenous lipoid pneumonia. Clinical and radiological manifestations|journal=Respiratory Medicine|volume=105|issue=5|year=2011|pages=659–666|issn=09546111|doi=10.1016/j.rmed.2010.12.001}}</ref>
-OR
-Effective measures for the secondary prevention of [disease name] include:
-*[Strategy 1]
-*[Strategy 2]
-*[Strategy 3]
 ==References==